NYSE · Medical - Diagnostics & Research

Danaher Corporation (DHR) Stock

$196.55 -1.26% NYSE: DHR Healthcare

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Valuation

MetricValue
Price$196.55
Market Cap$138.17B
P/E Ratio33.17
P/B Ratio2.29
P/S Ratio5.18
EPS (TTM)$5.04
52-Week High$242.80
52-Week Low$160.93
Dividend Yield0.75%

Financials & Margins

MetricValue
ROE7.08%
ROA4.19%
ROCE9.78%
Gross Margin20.91%
Operating Margin20.91%
Net Margin14.89%
Debt/Equity0.35
Current Ratio1.87

Annual Financials (USD)

Metric20212022202320242025
Revenue$29.5B$26.6B$23.9B$23.9B$24.6B
Operating Profit$8.1B$7.5B$5.3B$5.2B$5.1B
Net Profit$6.4B$7.2B$4.8B$3.9B$3.6B
EPS$8.61$9.64$6.38$5.29$5.04
Op Margin27.3%28.3%22.1%21.7%20.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$83.2B$84.3B$84.5B$77.5B$83.5B
Total Liabilities$38.0B$34.3B$31.0B$28.0B$30.9B
Cash$2.6B$6.0B$5.9B$2.1B$4.6B
Borrowings$23.3B$20.6B$19.5B$17.1B$18.4B

Latest News

Baird Adjusts Price Target on Danaher to $251 From $245, Maintains Outperform Rating MT Newswires · Jul 13, 2026 OmniAb Names Amechi Nwachuku Chief Operating Officer Business Wire · Jul 13, 2026 Cell Isolation Market/Cell Separation Market by Product, Cell Type, Source, Technique, Application, End User, Competition, Region - Global Forecast to 2031 GlobeNewswire · Jul 13, 2026 Abbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipment 24/7 Wall St. · Jul 10, 2026 Jim Cramer on Danaher: “I Don’t Want You Anywhere Near That One” Insider Monkey · Jul 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$8.4B$8.5B$7.2B$6.7B$6.4B
Investing Cash Flow$-14.3B$-3.4B$-8.5B$-3.4B$-2.4B
Financing Cash Flow$-16.0M$-95.0M$2.1B$-6.1B$-3.2B
Net Cash Flow$-3.4B$3.4B$-131.0M$-3.8B$2.5B
Free Cash Flow$7.1B$7.4B$5.8B$5.3B$5.3B

Valuation & Return Ratios

MetricValue
PEG Ratio
EV / EBITDA18.91
FCF Yield4.12%
Quick Ratio1.52
Interest Coverage19.38
Return 1Y-2.01%
Return 3Y-14.38%
Return 5Y-16.22%

Ownership

Insiders Held10.74%
Institutions Held84.49%
Institutions Float Held94.65%
Institutional HolderSharesReport Date
Blackrock Inc.51,640,6192026-03-31
Vanguard Capital Management LLC41,127,8102026-03-31
State Street Corporation27,894,1812026-03-31
FMR, LLC22,534,3292026-03-31
JPMORGAN CHASE & CO16,917,6492026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMGNAmgen Inc. $387.64 -1.39% 23.42 $209.21B 2.82%
BSXBoston Scientific Corporation $46.04 -0.04% 22.56 $68.43B 0.00%
GILDGilead Sciences, Inc. $132.73 -1.18% 17.57 $164.79B 2.46%
ISRGIntuitive Surgical, Inc. $353.10 -2.40% 54.82 $124.74B 0.00%
MCKMcKesson Corporation $888.56 -0.11% 23.00 $104.03B 0.42%

About Danaher Corporation

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

Danaher Corporation is led by CEO Rainer Blair, employs 61,000 people, headquartered in Washington, US, publicly traded since 1978.

Danaher Corporation (DHR) stock trades at $196.55 with a market capitalization of $138.17B. The stock is valued at a price-to-earnings (P/E) ratio of 33.17, price-to-book of 2.29, price-to-sales of 5.18. Over the past 52 weeks the stock has ranged between $160.93 and $242.80, and currently trades 19.0% below its 52-week high. It pays a dividend yielding 0.75%.

On profitability, Danaher Corporation generates a return on equity (ROE) of 7.08%, return on capital employed of 9.78%, an operating margin of 20.91%, a net profit margin of 14.89%.

In its most recent fiscal year, Danaher Corporation reported annual revenue of $24.6B, net profit of $3.6B, revenue has compounded at 2.0% a year over the last five years, profit at -0.2% a year.

The balance sheet shows a debt-to-equity ratio of 0.35 — a conservative balance sheet with little leverage risk, a current ratio of 1.87, total assets of $83.5B, $4.6B in cash and equivalents.

DHR has an average daily trading volume of 5,119,563 shares, a beta of 0.83.

Official website: www.danaher.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides